GPBAR1 and metabolic dysfunction-associated steatotic liver disease: As an agonist of TGR5, HDCA may play a role in modulating metabolism and energy expenditure, particularly showing potential therapeutic value in the treatment of metabolic disorders, such as obesity, diabetes, dyslipidemia, atherosclerosis, NAFLD, and neurological conditions (55).